Department of Physiology and Pharmacology

/med/depts/physpharm/

Welcome

molecular medicine track (MOME)

/med/depts/physpharm/

Related Links

 



Contact Us

Health Science Campus
Block Health Science Building

Mail Stop #1008
3000 Transverse Drive
Toledo, Ohio 43614-2598
Phone: 419.383.4182
Fax: 419.383.2871

webmaster@utoledo.edu

Terry D. Hinds, Jr., Ph.D.

 Terry Hinds
  

      

Assistant Professor, Department of Physiology and Pharmacology

Phone: (419) 383-4465
Fax: (419) 383-2871

E-mail: Terry.Hinds@utoledo.edu

 

Research Interests:

My lab focuses on the involvement of the heme oxygenase (HO) system and nuclear receptors in metabolic diseases, which includes obesity and diabetes as well as cancer.  The HO system maintains metabolic balance by signaling to biliverdin reductase that produces the antioxidant, bilirubin.  My lab looks at the how HO, bilirubin, and nuclear receptors signal for balance in metabolic disorders.  We are currently studying how bilirubin can aid the nutrient and lipid sensing nuclear receptors, the PPARs (PPAR alpha, PPAR gamma, and PPAR delta), in the maintenance of metabolic homeostasis. Other nuclear receptors are stress sensing, such as the glucocorticoid receptors (GRalpha and GR beta), which regulate the immune system balance and glucose production during times of stress.  Together, the PPARs and GRs regulate the balance of lipids and glucose as well as maintain growth of cancer cells.

Current studies:

Project 1: 
We are working on drug targeting of the heme oxygenase system in the prevention of obesity and the link between fat tissue in obesity-induced hypertension.  Diet induced obesity results in elevated levels of glucose and fatty acids in blood, liver and fat tissues, resulting in the enhanced production of reactive oxygen species (ROS).  The oxidative stress magnifies the adverse effects of obesity by inducing inflammation of tissues, leading to the development of non-alcoholic fatty liver disease (NAFLD) as well as vascular dysfunction.

Project 2:  We are looking at the role of the glucocorticoid receptors in prostate and bladder cancer.  This is a clinical investigation in collaboration with the UT Department of Urology and Department of Pathology, which includes analysis of human specimens taken from patients at the University of Toledo Health Center.  We have been screening human cancer samples for expression of the GR isoforms, in which, one may be linked to metastasis.  In these studies, we are also using human cancer cells to understand the involvement of the receptors in cancer and drug targeting.  Interestingly, we have discovered that metabolic growth factors such as insulin and epidermal growth factor enhance the expression of the receptor and lead to exacerbated growth.  We are currently looking at drugs that can inhibit the function of the GR isoform that leads to growth.

Project 3:  In our newest study, we are analyzing the biliverdin reductase (BVRA and BVRB) in metabolic disorders such as obesity and diabetes, and potential drug targeting of the enzymes.  On this project, we are collaborating with the University of Mississippi Medical Center as well as the Center for Drug Design and Development, which are building us new drug compounds that can target the BVR isozymes as well as nuclear receptors in the prevention of obesity and diabetes.  This project is of novel drug design that may lead to a new class of drugs known as THin Molecules.

Appointments:

2016-Assistant Professor, Tenure Track, Department of Urology, University of Toledo
2014-Graduate Faculty Associate, Department of Kinesiology, University of North Carolina at Charlotte
2013 - Assistant Professor, Tenure Track, Physiology & Pharmacology, University of Toledo
2012 - Instructor, Organ Systems course in Physiology & Pharmacology, University of Toledo
2010 - Postdoctoral Fellow, Physiology & Pharmacology, University of Toledo
2007 - Guest lecturer for Methods in Molecular Biology course, Medical University of Ohio
2004 - Anatomy and Physiology I & II, Adjunct Instructor, Shawnee State University

Awards and Commendations:

2017                Dean's Award for Research Excellence in the New Investigator category, University of Toledo
2016                deArce-Koch Memorial Fund Award
2016                Faculty Innovator Award, Department of Physiology and Pharmacology, University of Toledo
2015                President of the Ohio Physiological Society
2014                Research Scientist Development Award (K01) NIH/NHLBI
2014                NIH LRP Award for Health Disparities Research
2013                NIH NHLBI program, PRIDE-Functional and Applied Genomic of Blood Disorders
2010                Selected for Oral Presentation in “Hot topics of Physiology”, Keystone Symposia,
                        Nuclear Receptors: Signaling, Gene Regulation and Cancer, Keystone, CO
2010                Cancer, Genetics, and Signaling (CGS) Group at the National Cancer Institute-Frederick.
                        Selected in Top 10 at the NIH Graduate Student Research Festival (200 total).
2010                Abstract Award, Endocrine Society National Meeting, San Diego, CA
2009-10           Ruth L. Kirschstein National Research Service Award (NRSA), NIDDK, NIH
2001                Thinker of the Year Award Recipient, Civic Development Group


Patents:

Patent - D2009-23– Provisional Patent Application
For: “Glucocorticoid Receptor Beta in Mice”
Inventors: Terry D. Hinds, Jr. (50%) and Edwin R. Sanchez (50%)
Ser. No. 61/333,708 provisional patent filed May 11, 2010
MST File No.: 1-50554
LAW OFFICES OF MACMILLAN, SOBANSKI & TODD, LLC
*Provisional Patent


Patent - D2010-63– Provisional Patent Application
For: “Methods and Compositions for Treating Dyslipidemia and Obesity using Protein Phosphatase 5 as a Drug Target.”
Inventors: Terry D. Hinds, Jr. (50%) and Edwin R. Sanchez (50%)
Ser. No. 61/454,928 provisional patent filed March 21, 2011
MST File No.: 1-52813
LAW OFFICES OF MACMILLAN, SOBANSKI & TODD, LLC


Patent - D2016-49 – Provisional Patent Application
For: “Targeting of human glucocorticoid receptor beta in cancer.”
Inventors: Terry D. Hinds, Jr. (90%) and Lucien McBeth (10%)
US Serial No.: 62/306,209 filed March 10, 2016
MST File No.: 1-57720
LAW OFFICES OF MACMILLAN, SOBANSKI & TODD, LLC


Patent - D2016-29 – Provisional Patent Application
For: “Thin Molecules for the Treatment of Obesity and Type II Diabetes.”
Inventors: Terry D. Hinds, Jr. (70%), Chris Trabbic (20%), and David Stec (10%)
US Serial No.: 62/301,134 filed February 29, 2016
MST File No.: 1-57768
LAW OFFICES OF MACMILLAN, SOBANSKI & TODD, LLC


Licensing:

          Resource: Mouse Glucocorticoid Receptor beta Polyclonal Antibody
          Inventors: Terry D. Hinds, Jr. and Edwin R. Sanchez
          http://utoledo.technologypublisher.com/technology/11366


Editorial Board Member:

Cell Stress 2016—present (Editorial Board includes 5 Nobel prize winners and 33 members of the National Academy of Sciences)
Nuclear Receptor Research 2016—present
International Journal of Clinical Endocrinology and Metabolism 2015—present
Annals of Obesity & Disorders 2015—present
International Journal of Clinical Pharmacology and Toxicology 2015—present
Frontiers in Pharmacology - Drug Metabolism and Transport Specialty Section 2015—present
Diabetes Research - Open Journal 2014—present
Obesity Research - Open Journal 2014—present


Publications

Please click here for a complete list of Dr. Hinds' publications.


Last Updated: 4/26/17